"We now eagerly await rapid recruitment to the trial so that we can assess both the safety of the vaccine and its ability to produce neutralising antibodies which would indicate an effective response against COVID-19". After which this vaccine may be available to the common people.
"The first participant marks an important step for our saRNA vaccine platform, which has never before been trialled in humans", Shattock is quoted as saying in an article on the trial process on the college's website. A number of other healthy volunteers are waiting to also be given the first dosage of the trial vaccine in the upcoming days.
"Starting Tuesday, volunteers with a negative blood test were administered the vaccine". Gates believes it is possible to scale up to 10 billion doses of a successful vaccine in two years in order to achieve herd immunity, he said at the summit.
"Usually the United States plays a role in global problem-solving, so rather than withdrawing from World Health Organization, they'd be involved, collaborating with other countries, not just trying to cast blame", Gates said.
After this first phase, another trial is being planned for October, involving 6,000 people.
Some recombinant vaccines, however, require booster shots for ongoing protection.
The novel coronavirus uses its spike protein to bind to ACE2 receptors on human cells and subsequently infect them.
It is one of the world's best hopes for a vaccine.
It also said the viral load in the test animals decreased noticeably, reducing the virus' damage to lung tissues.
How does the vaccine work?
"Now more than ever, nations need to work in close partnership between the government and private sectors to create new initiatives, launch programs, develop policies, drive rigorous research, and develop capacity".
In mid-June, US biotech company Moderna finalized its protocol for the phase three trial of its COVID-19 nucleic acid vaccine candidate mRNA-1273. The participants in the Phase 2-3 trial will be randomised to receive either one or two doses of the candidate vaccine or a control vaccine (MenACWY) that protects against four strains of meningococcal bacteria.
The factories had estimated the price of a vaccine dose at US$30, at mass production of 2 million doses, according to Dr Kiat.